Ceftriaxone + Tazobactam Injection

Description

Product Description: Ceftriaxone + Tazobactam Injection combines the powerful antibiotic ceftriaxone with the beta-lactamase inhibitor tazobactam, offering enhanced efficacy against a wide range of bacterial infections. This combination therapy is designed to overcome bacterial resistance mechanisms, particularly those mediated by beta-lactamase enzymes, providing a comprehensive approach to treating complex infections.

Indications and Usage: Ceftriaxone + Tazobactam Injection is indicated for the treatment of moderate to severe bacterial infections caused by susceptible organisms. It is commonly prescribed for infections of the respiratory tract, urinary tract, skin and soft tissue, intra-abdominal infections, septicemia, and bacterial meningitis.

Dosage and Administration: Dosage and administration should be determined by a qualified healthcare professional based on the severity of the infection, the patient's age and weight, and the susceptibility of the causative bacteria. Ceftriaxone + Tazobactam is typically administered intravenously once or twice daily. Dosage adjustments may be necessary in patients with impaired renal function.

Dosage Forms and Strengths: Ceftriaxone + Tazobactam Injection is available as a sterile powder for reconstitution in various strengths, typically ranging from 1 gram of ceftriaxone combined with 0.125 grams of tazobactam to 2 grams of ceftriaxone combined with 0.25 grams of tazobactam per vial.

Contraindications: Ceftriaxone + Tazobactam Injection is contraindicated in patients with known hypersensitivity to cephalosporin antibiotics, beta-lactamase inhibitors, or any component of the formulation. It should not be used in patients with a history of severe allergic reactions to penicillin or other beta-lactam antibiotics.

Warnings and Precautions: Serious hypersensitivity reactions, including anaphylaxis, have been reported with the use of ceftriaxone + tazobactam. It should be used with caution in patients with a history of allergies, asthma, or other allergic conditions. Prolonged use may result in the overgrowth of non-susceptible organisms, including fungi. Clostridium difficile-associated diarrhea has been reported with the use of nearly all antibacterial agents, including ceftriaxone + tazobactam.

Adverse Reactions/Side Effects: Common adverse reactions associated with ceftriaxone + tazobactam include diarrhea, nausea, vomiting, rash, and injection site reactions. Serious adverse reactions may include severe allergic reactions, Clostridium difficile-associated diarrhea, and hepatic dysfunction.

Drug Interactions: Ceftriaxone + Tazobactam may interact with other medications, including probenecid, which may increase the serum concentration of ceftriaxone by reducing renal excretion. Concurrent use with calcium-containing intravenous solutions may result in precipitation and should be avoided.

Use In Specific Populations Description: Use of ceftriaxone + tazobactam in pregnant women should be weighed against the potential risks to the fetus. It is excreted in breast milk; caution should be exercised when administering to nursing mothers. Safety and effectiveness in pediatric patients have been established for certain indications and age groups.

How Supplied/Storage and Handling: Ceftriaxone + Tazobactam Injection is supplied as sterile powder in single-dose vials. It should be stored at controlled room temperature (20°C to 25°C) and protected from light.